Clinical impact of <i>TP53</i> functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy
Specific TP53 MMs may identify sub-groups of patients who benefit from Bevacizumab-based systemic therapy and these findings could lead to novel tailored treatment strategies in this setting.
Authors
- Alberto Patriti (ORCID: https://orcid.org/0000-0003-2414-268X)
- Francesco Graziano (ORCID: https://orcid.org/0000-0002-4896-1842)
- Rita Chiari (ORCID: https://orcid.org/0000-0002-7649-273X)
- Tiziana Tamburrano
- Silvia Palladino (ORCID: https://orcid.org/0009-0001-3498-6555)
- Nicholas W. Fischer (ORCID: https://orcid.org/0000-0003-4672-0532)
- Vincenzo Catalano (ORCID: https://orcid.org/0000-0002-8380-7736)
- Donatella Sarti (ORCID: https://orcid.org/0000-0002-8031-7846)
- Paolo Giordani (ORCID: https://orcid.org/0000-0003-0087-7315)
- Filippo Petrelli (ORCID: https://orcid.org/0000-0002-2179-4255)
- David M. Malkin (ORCID: https://orcid.org/0000-0001-5752-9763)
- Annamaria Ruzzo
Institutions
- University of Toronto (CA)
- University of Urbino (IT)
- Hospital for Sick Children (CA)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1093/oncolo/oyae277
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57